Editors:
- This book features chapters written by internationally known experts in the field
- This book will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects and medical physics that deals with radiation dosimetry
- This book will provide future prospects for overcoming resistance and enhancing the efficacy of Ibritumomab
Part of the book series: Resistance to Targeted Anti-Cancer Therapeutics (RTACT, volume 18)
Buy it now
Buying options
Tax calculation will be finalised at checkout
Other ways to access
This is a preview of subscription content, log in via an institution to check for access.
Table of contents (10 chapters)
-
Front Matter
-
Back Matter
About this book
This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.
Editors and Affiliations
-
Institute of Advanced Clinical Medicine, Kindai University Faculty of Medicine, Osaka, Japan
Makoto Hosono
-
GIP Arronax, Nantes-Saint-Herblain, France
Jean-François Chatal
About the editors
Makoto Hosono, MD, PhD, is a Professor of Radiology and Nuclear Medicine, Institute of Advanced Clinical Medicine, Kindai University Faculty of Medicine, Japan, and serves as a member of Committee 3, International Commission on Radiological Protection.
Jean-François Chatal, MD, PhD, is an Emeritus Professor of Nuclear Medicine at the University of Nantes, France. He is one of the international leaders who developed radioimmunotherapy, that is, therapy using radiolabeled anti-tumor antibodies. He created and headed an INSERM research laboratory and also initiated the installation of a cyclotron institute termed ARRONAX for the production of novel radionuclides for nuclear medicine.
Bibliographic Information
Book Title: Resistance to Ibritumomab in Lymphoma
Editors: Makoto Hosono, Jean-François Chatal
Series Title: Resistance to Targeted Anti-Cancer Therapeutics
DOI: https://doi.org/10.1007/978-3-319-78238-6
Publisher: Springer Cham
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: Springer International Publishing AG, part of Springer Nature 2018
Hardcover ISBN: 978-3-319-78237-9Published: 07 May 2018
Softcover ISBN: 978-3-030-08652-7Published: 08 January 2019
eBook ISBN: 978-3-319-78238-6Published: 24 April 2018
Series ISSN: 2196-5501
Series E-ISSN: 2196-551X
Edition Number: 1
Number of Pages: XIII, 158
Number of Illustrations: 4 b/w illustrations, 14 illustrations in colour
Topics: Cancer Research